| Deal value | $1.3B |
|---|---|
| Share of market cap | 105.7% |
| Share of annual revenue | 232558.1% |
Key highlights
- Shareholders to receive $20.00 per American Depositary Share in cash, representing a 130% premium
- Total transaction value estimated at $1.3 billion equity value and $1.1 billion enterprise value
- Acquisition focuses on Divesiran, a Phase 2 siRNA candidate for polycythemia vera
- Deal to be executed via a U.K. scheme of arrangement with expected closure in Q1 2027
- Shareholders representing 14% of voting power have already committed to supporting the transaction
What Is the Deal?
Merck KGaA, Darmstadt, Germany, will acquire all issued and to be issued share capital of Silence Therapeutics for $6.6667 per ordinary share, translating to $20.00 per American Depositary Share (ADS). The transaction is structured as an all-cash acquisition valuing the biotechnology firm at approximately $1.3 billion. Subject to approval by Silence shareholders and the High Court of Justice of England and Wales, the deal is expected to conclude in the first quarter of 2027. Regulatory clearances are required under the Hart-Scott-Rodino Act in the United States and German antitrust regulations before the transfer is finalized.
Up 128.1% since our story on 19 Oct: $8.68 when we broke it → $19.80 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $19.58 |
|---|---|
| 20 Oct | $19.61 |
| 21 Oct | $19.67 |
| 22 Oct | $19.66 |
| 23 Oct | $19.67 |
| 26 Oct | $19.78 |
| 27 Oct | $19.78 |
| 28 Oct | $19.71 |
| 29 Oct | $19.80 |
| 30 Oct | $19.75 |
| 2 Nov | $19.76 |
| 3 Nov | $19.78 |
| 4 Nov | $19.80 |
| 5 Nov | $19.72 |
| 6 Nov | $19.73 |
| 9 Nov | $19.75 |
| 10 Nov | $19.79 |
| 11 Nov | $19.77 |
| 12 Nov | $19.80 |
| 13 Nov | $19.83 |
| 16 Nov | $19.80 |
Deal Structure & Terms
- Consideration is 100% cash with no stock-based components or earnout provisions disclosed
- Offer represents an 82% premium to the 30-day volume-weighted average price of $10.99
- Transaction requires 75% shareholder approval by value at the upcoming Scheme Meeting
- Silence ADSs will be delisted from the Nasdaq Stock Market following the effective date
- Specific securityholders have entered voting and support agreements for 14% of voting securities
Strategic Rationale
The acquisition is designed to strengthen Merck KGaA's specialty and rare disease pipeline, specifically through the addition of Divesiran. Divesiran is a Phase 2 siRNA candidate currently being evaluated for the treatment of polycythemia vera, a rare blood cancer. Merck KGaA intends to leverage its global scale and commercial resources to accelerate Divesiran’s transition into Phase 3 clinical development. This move follows Merck KGaA's previous acquisition of SpringWorks Therapeutics, signaling a continued commitment to expanding its presence in targeted medical fields with high unmet needs using external innovation.
Business Overview
Silence Therapeutics is a London-based clinical-stage biotechnology company that specializes in precision-engineered medicines using its proprietary siRNA platform. The company's technology is designed to inhibit the expression of specific disease-causing genes in the liver. While Silence recently reported a cash runway extending into 2029, it remains in the pre-revenue stage typical of clinical biotech firms. The company’s pipeline focuses on hematology and cardiovascular diseases, with its lead program SANRECO (Divesiran) preparing for a pivotal Phase 3 trial initiation in the first half of 2027.
Industry Landscape
This deal underscores the ongoing consolidation in the biopharmaceutical sector, where large-cap entities seek to acquire de-risked Phase 2 and Phase 3 assets to bolster their future growth. The siRNA modality has gained significant traction as a validated therapeutic approach, drawing interest from major pharmaceutical players looking to diversify their platforms. By incorporating Silence's assets, Merck KGaA competes more directly with other RNA-interference specialized companies. This transaction highlights the premium value currently placed on late-stage biotech assets that address rare diseases with limited existing treatment options.
Management commentary
“We are pleased to have reached this agreement with Merck KGaA, Darmstadt, Germany, which is the result of a competitive sale process and delivers significant, immediate and certain value to our shareholders.”
“The planned acquisition of Silence Therapeutics will strengthen our capabilities to serve patients with targeted specialty and rare diseases.”
| Share price | $8.68 |
|---|---|
| Market cap | $1.2B |
| Revenue (annual) | $559,000 |
| 1-month price change | -30.56% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Silence Therapeutics plc announcing a definitive agreement to be acquired by Merck KGaA.
Track Silence Therapeutics plc live
Get the next Silence Therapeutics plc SEC filing seconds after it lands.



